MDI-114215 |
カタログ番号GC92409
One-Click Copy Product Info
|
MDI-114215 is an allosteric inhibitor of LIM kinase 1 (LIMK1) and LIMK2 (IC50s = 19.95 and 26.92 nM, respectively).
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
MDI-114215 is an allosteric inhibitor of LIM kinase 1 (LIMK1) and LIMK2 (IC50s = 19.95 and 26.92 nM, respectively). It is selective for LIMK1 and LIMK2 in a panel of 468 kinases but does bind to cyclin-dependent kinase 7 (Cdk7), MAP kinase kinase 7 (MKK7), vaccinia-related kinase 2 (VRK2), and phosphorylated Abl1 at 300 nM. MDI-114215 is also selective for LIMK1 and LIMK2 in a panel of 44 receptors, ion channels, transporters, and enzymes but does bind to cannabinoid 1 (CB1) receptor at 10 µM. It reduces the levels of cofilin phosphorylated by p21-activated kinase 1 (PAK1) in SH-SY5Y cells (IC50 = 50.12 nM). MDI-114215 (3 µM) enhances long-term potentiation (LTP) in hippocampal slices from Fmr1 knockout mice, which lack the gene encoding fragile X mental retardation 1 protein (FMRP).
| Cas No. | SDF | ||
| Chemical Name | N-(cyclopropylmethyl)-N-(4-((2-hydroxyethyl)amino)benzyl)-4-(N-phenylsulfamoyl)benzamide | ||
| Canonical SMILES | O=S(NC1=CC=CC=C1)(C2=CC=C(C(N(CC3CC3)CC4=CC=C(NCCO)C=C4)=O)C=C2)=O | ||
| Formula | C26H29N3O4S | M.Wt | 479.595 |
| 溶解度 | DMSO: Soluble: ≥ 10 mg/ml; Ethanol: Soluble: ≥ 10 mg/ml | Storage | -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0851 mL | 10.4255 mL | 20.8509 mL |
| 5 mM | 417 μL | 2.0851 mL | 4.1702 mL |
| 10 mM | 208.5 μL | 1.0425 mL | 2.0851 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)